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Men who develop prostate cancer (PCa) increasingly have one of the co-morbidities 
associated with a Western lifestyle that are characterized by hyperinsulinemia, hypergly-
cemia and increased expression of insulin-like growth factors-I (IGF-I) and IGF-II. Each 
have been associated with poor prognosis and more aggressive cancers that exhibit 
increased metabolism and increased glucose uptake. The insulin receptor (IR) has two 
splice isoforms IR-A and IR-B: IR-A has a higher affinity for IGF-II comparable to that 
for insulin, whereas the IR-B isoform predominantly just binds to insulin. In this study, 
we assessed alterations in the IR-A and IR-B isoform ratio and associated changes 
in cell proliferation and migration of PCa cell lines following exposure to altered con-
centrations of glucose and treatment with IGF-II and insulin. We observed that where 
IR-B predominated insulin had a greater effect on migration than IGF-II and IGF-II was 
more effective when IR-A was the main isoform. With regard to proliferation IGF-II was 
more effective than insulin regardless of which isoform was dominant. We assessed the 
abundance of the IR isoforms both in vivo and in vitro and observed that the majority 
of the tissue samples and cell lines expressed more IR-A than IR-B. Alterations in the 
isoforms in response to changes in their hormonal milieu could have a profound impact 
on how malignant cells behave and play a role in promoting carcinogenesis. A greater 
understanding of the mechanisms underlying changes in alternative splicing of the IR 
may provide additional targets for future cancer therapies.
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inTrODUcTiOn
Following cloning of the insulin receptor (IR) cDNA by both Ullrich et al. and Ebina et al. in 1985, 
it was observed that the cDNAs were of different lengths suggesting that the IR existed in two 
different forms (1, 2). Later defined as isoform A (IR-A), in which exon 11 is skipped and isoform 
B (IR-B) that includes exon 11. A number of studies began to report different characteristics of 
the two isoforms: Mosthaf et al. observed that when the cDNAs encoding the two isoforms were 
expressed in Rat1 cells, IR-A exhibited a higher affinity for insulin than the IR-B isoform (3). 
Yamaguchi et al. reported differential ligand binding to the two isoforms: labeled-insulin had a 
faster “on and off rate” for IR-A compared with IR-B (4, 5). These data suggested that the iso-
forms may perform slightly different functions as receptors for insulin but potentially much more 
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profound differences became clear when Frasca et  al. deter-
mined that IR-A and not IR-B acted as a high-affinity receptor 
for insulin-like growth factor-II (IGF-II) (6). Along with IGF-I, 
IGF-II is a peptide belonging to the IGF family that in addition 
to the two ligands, also comprise six high-affinity IGF binding 
proteins (IGFBPs), IGFBP-proteases, together with the IGF-I 
and IR receptors and a non-signaling IGF-IIR, that acts to clear 
excess IGF-II: components of this system are often dysregulated 
in a number of different cancers, including that of the prostate 
(7). Prostate cancer (PCa) is the fifth most common cause of 
cancer death worldwide for males, and the eighth most common 
cause of cancer death overall. It is predicted that there will be 
27,540 deaths from PCa in the United States in 2015 (American 
Cancer Society: http://www.cancer.org/cancer/prostatecancer). 
The major issue in the management of PCa is the inability to 
distinguish between the majority that are slow growing and 
localized, prostate tumors from the less common but more 
invasive, aggressive, and metastatic PCas that will impact on 
mens’ lives. Whereas cancers localized to the prostate are effec-
tively cured through surgery or radiotherapy, few treatments are 
available for men with metastatic or hormone-therapy resistant 
PCa (8). Population studies have clearly implicated metabolic 
factors (IGFs/insulin) as contributors to disease progression and 
poor response to therapy (9). Both IGF-I and IR receptors are 
present on human PCas (10) and as with other cancers, it has 
been reported that the IR-A as opposed to the IR-B isoform is 
predominant in the cancer tissue compared to levels observed 
in the benign prostate samples (11). In this study, we assessed 
alterations in the IR-A and IR-B isoform ratio and associated 
changes in cell proliferation and migration in PCa cell lines 
following exposure to altered concentrations of glucose and 
treatment with IGF-II and insulin. We also examined the abun-
dance of the IR isoforms in areas of benign tissue and invasive 
prostate carcinoma from the same patient in a small cohort of 
PCa patients diagnosed between 2000 and 2009 with clinically 
localized hormone-naïve adenocarcinoma of the prostate.
MaTerials anD MeThODs
Materials
All chemicals, unless otherwise stated, were purchased from 
Sigma (Gillingham, UK). All siRNAs and the transfection 
reagent, Saint-Red were purchased from Synvolux Therapeutics 
B.V. (Groningen, The Netherlands). Fetal bovine serum (FBS) 
was purchased from Invitrogen (Paisley, UK), DMEM-25  mM 
glucose (BF-709) and DMEM-5  mM glucose (BF-708), RPMI 
1640, penicillin–streptomycin solution and l-glutamine were 
bought from Lonza (Basel, Switzerland). Human, recombinant 
IGF-II was obtained from GroPep (Thebarton, Australia) and 
Actrapid (human insulin) was purchased via Southmead Hospital 
Pharmacy.
cell culture
We used PCa cell lines: androgen-independent DU145, PC3 and 
androgen-dependent LNCaP and VCaP that were purchased 
from the American Type Culture Collection (ATCC) that 
authenticates their cell lines using short tandem repeat (STR) 
DNA profiles; the cells were used for a maximum of 10 passages. 
DU145, PC3, and VCaP cells were grown in DMEM growth 
media (GM) supplemented with 10% FBS, penicillin–strepto-
mycin (50  IU/ml) and 1% l-glutamine solution (2  mM) and 
LNCaP cells were cultured in RPMI 1640 GM supplemented 
with 10% FBS and antibiotics. Cells were maintained in a 
humidified 5% carbon dioxide atmosphere at 37°C. For all 
experiments, cell lines were seeded in 5  mM glucose GM for 
24  h and then transferred to either serum-free media (SFM); 
supplemented with sodium bicarbonate (1  mg/ml), bovine 
serum albumin (0.2 mg/ml), and transferrin (0.01 mg/ml) for 
a further 24 h.
cell counting
Floating cells were collected and mixed with adherent cells after 
trypsinization, and the resulting cell suspension was loaded onto 
a hemocytometer (1:1) with the dye Trypan blue, which is taken 
up by dead cells. Both viable and dead cells were counted, from 
which both the percentage of dead cells and total cell number 
were calculated.
real-Time Polymerase chain reaction 
and Quantitative Polymerase chain 
reaction
Real-time polymerase chain reaction (RT-PCR) and quantita-
tive polymerase chain reaction (q-PCR) were used to analyze 
the expression of the IR and the IR isoforms. Total RNA was 
extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. Two micrograms 
of total RNA was used for cDNA synthesis with random hex-
amers. RNA was quantified using a Nano photometer (used at 
a 260/280 ratio of between 1.6 and 2.0). For RT-PCR, primers 
for detecting both IR-A and IR-B were designed “in-house”: 
forward 5′ GGAAGACGTTTGAGGATTAC 3′ and reverse 5′ 
TCGAGGAAGTGTTGGGGAAAG3′. PCR was carried out 
using HotStarTaq DNA polymerase (Qiagen, Manchester, UK) 
per the manufacturer’s recommendations. In brief, the PCR 
program was run at 95°C (5 min) [95°C (1 min), 59°C (1 min), 
and 72°C (1  min)  ×  40] and 72°C (10  min). PCR products 
were run on a 2% agarose gel and detected using an ultraviolet 
transilluminator (Biorad Gel Doc 1000, Hertfordshire, UK). To 
verify the IR-A and B PCR products, they were commercially 
sequenced (Source BioScience, Nottingham, UK) and were veri-
fied to be the sequence listed in GENE BANK (NM_000208.2). 
Quantitative real-time PCR was performed using Green 
JumpStart SYBR and an ABI StepOne Plus Realtime PCR System 
(Applied Biosystems; Life Technologies, Paisley, UK). In brief, 
the PCR program was run at 95°C (2  min) followed by (95°C 
(15 s) and 60°C (30 s) × 40). Reactions were run in duplicate in 
three independent experiments. Expression data were normal-
ized to the geometric mean of a housekeeping gene (18S) to 
control the variability in expression levels and were analyzed 
using the 2−ΔΔCT method. Melting curve analysis was performed 
each time to confirm specific PCR amplification. PCR primers 
were designed using OligoPerfect online software from Qiagen 
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(Manchester, UK) under consideration of the special design crite-
ria for real-time RT-PCR primers, spanning the junction between 
exons. For IR forward 5′TGACAACGACCAGTGTGGAG 3′ 
and IR reverse 5′ GCAGCCGTGTGACTTACAGA 3′, for 18S 
forward 5′GATGTAGTTGCTTGGGACCCA 3′ and 18S reverse 
5′TGGAGATAACACTCTAAGCATAACTAAAGGT 3′.
Transfection of Cells with siRNA
Cells were transfected with siRNA using Saint-Red following 
the manufacturer’s instructions and as described previously 
(12). IR-A and IR-B were knocked down using specifically 
designed siRNAs that spanned exon 11 to 12 of the IR (for 
IR-B silencing) and exon 10 to12 (for IR-A silencing): target 
sequence IR-A; UUUCCGAGAUGGCCUGGGGUU. IR-B; 
CGAGGACCCUAGGCCAUCUUU. A non-silencing (NS) nega-
tive control siRNA was used as a second control.
Migration Assay
A cell suspension of DU145 cells (70 μl: 0.5 × 104 cells/ml of 5 mM 
GM) was placed into each chamber of an Ibidi Culture-Insert 
(Thistle Scientific Ltd, Glasgow, UK) in a well of a 6-well plate. 
After cells had attached, reached confluency in the chambers 
(100%) and formed a tight junctioned gap, the culture insert was 
gently removed and cells were exposed to either 5 or 25 mM SFM 
in the presence or absence of IGF-II or insulin (each at 100 ng/
ml) for the times denoted in the figure legend. Microscopy images 
(Leica DM IRB, Milton Keynes, UK) were assessed using Image J 
to measure changes in the width of the gap.
Western Blotting
Cell lysates were run on an 8% SDS-PAGE and transferred to 
Hybond-C nitrocellulose membrane (GE Healthcare, Bucks, 
UK). Proteins were probed with anti-IR (1:500 Santa Cruz, 
Heidelberg, Germany) anti-GAPDH or anti-β actin (Millipore, 
Hertfordshire, UK, both 1:10,000), anti-IR-β (1:750 Santa Cruz, 
Heidelberg, Germany), anti-p-Akt, anti-Akt, anti-p-MAPK and 
anti-IGF-IR (all 1:1000), and anti-MAPK (1:500) and anti-p-IGF-
IR (1:750) (all from Cell Signalling, Leiden, The Netherlands) 
with secondary antibodies as follows: anti-rabbit (1:2500; IR, 
IR-β, p-Akt, Akt, p-MAPK, MAPK, p-IGF-IR, and IGF-IR 
all at 1 :2000) and anti-mouse (1:10,000 for both GAPDH and 
β-actin). All antibodies were diluted following the manufacturer’s 
instructions. Proteins were visualized using supersignal west dura 
ECL solution (Thermo Fischer, Ulm, Germany) and the UVP 
ChemiDoc-IT Imaging System (UVP, Bio-Rad, Hertfordshire, 
UK) and analyzed using Vision Works ls Analysis Software (UVP 
Inc., Upland, CA, USA).
human Tissue samples
This study used tissue samples from 37 PCa patients diagnosed 
between 2000 and 2009 with clinically localized hormone-naïve 
adenocarcinoma of the prostate. The formalin fixed paraffin 
embedded (FFPE) PCa samples under approval of National 
Research Ethics Committee (NRES No. 09/H0102/48) were kindly 
assessed in collaboration with Dr. Rachel Hagen (University of 
the West of England, Bristol, UK). Tissue samples were fixed in 
neutral buffered saline for at least 24 h before processing and the 
wax blocks were stored at room temperature. Three consecutive 
10-μm wax curls were cut from each sample case. An FFPE 
RNeasy Kit (Qiagen, Manchester, UK) was used to isolate tissue 
RNA; each wax curl was placed in a 1.5 ml Eppendorf and 1 ml 
of Histoclear was used to deparaffinise at 56 for 5  min. Tissue 
was pelleted by centrifugation and the Histoclear removed; the 
pellet was washed twice with 70% ethanol. After 10–15 min of 
air-drying, lysis buffer containing proteinase K (from kit) was 
added to the sample that was then incubated at 56 for 16 h. After 
proteinase K digestion the sample was incubated at 80 for 15 min 
and placed on ice for another 3 min. Samples were centrifuged 
and the supernatant added to 1 ml of Trizol reagent followed by 
the standard RNA isolation and RT-PCR protocol described in 
RT and q-PCR section above to assess the expression of the IR-A 
and B isoforms.
statistical analysis
Data show the mean SEM. Data were analyzed with SPSS 12.0.1 
for Windows using one-way ANOVA followed by least significant 
difference post hoc test. A statistically significant difference was 
considered to be present at p < 0.05.
resUlTs
insulin receptor isoform Profile in 
Prostate cancer cell lines
Using RT-PCR, we observed that PC3, LNCaP (low and high 
passage) and VCaP cells each expressed less of the IR-B isoform 
compared to IR-A. By contrast, the DU145 cell line exhibited 
the opposite profile having more IR-B than the IRA isoform 
(Figure 1A). q-PCR confirmed these observations by assessing 
the percentage of the IR-B isoform compared to the total amount 
of the IR. DU145 cells exhibited the highest IR-B expression 
(63.4%), while PC-3 and LNCaP cells predominantly expressed 
IR-A over IR-B (7.7 and 4.3%, respectively, of IR-B) and VCaP 
cells had almost no signal for IR-B (0.4%) (Figure 1B). Each of 
the cell lines expressed the IR with abundance being higher in 
the PC-3, VCaP, and LNCaP cells compared with the DU145 cells 
with mRNA levels also being lowest in DU145 and highest in PC3 
cells (Figures 1Ci,ii,iii).
Manipulation of the ir isoforms
siRNA to Silence the IR-A and IR-B Isoforms
Using RT-PCR with increasing concentrations of the IR-B siRNA, 
we observed effective silencing in DU145 cells with 50 nm siRNA 
for 24 h and this was sustained for 72 h (Figures 2A–C). q-PCR 
confirmed effective silencing of the IR-B isoform at each time 
point (24, 48, and 72 h; p < 0.05, respectively) and also showed 
that a reduction in the IR-B isoform relative to the IR or the 
reference gene (18S rRNA) was not associated with a reduction 
in absolute levels of the IR mRNA or protein up to 72 h (Figure 
S1A,B in Supplementary Material). We were unable to silence 
the IR-A isoform in DU145 cells despite varying the concentra-
tion of the siRNA or the exposure time (data not shown). In the 
other three PCa cell lines that we investigated (LNCaP, PC3, or 
VCaP), all express less than 10% of their IR in the IR-B isoform, 
we were unable to silence either IR-A or IR-B. However, using the 
FigUre 1 | (a) DU145, PC-3, LNCaP (low passage P18 and high passage P74) and VCaP cells were cultured in GM for 72 h followed by RNA extraction and IR-A 
and IR-B assessment detected by RT-PCR. The size of IR-B and IR-A were 171bp and 135bp, respectively. (B) q-PCR was used to detect the percentage of IR-B 
expression compared to total IR expression in different cell lines. IR-B, IR, and reference gene 18s primer pairs were used to amplify the signal of each target gene. 
The graph shows the percentage of IR-B compared to IR: the error bars represent the SE of the mean of the repeats and each experiment was performed in triplicate 
(n = 3). (c) (i) Western immunoblot of whole cell lysates extracted from DU145, PC-3, LNCaP, and VCaP cells after the cells had reached a confluence of 80% in GM 
to show the abundance of the IR relative to GAPDH used as a loading control. This is representative of blots performed at least three times. The optical density 
measurements showing the mean of the three repeats are shown in (c) (ii). (c) (iii) shows q-PCR of mRNA levels for the IR in DU145, LNCaP, and PC3 cells (n = 3).
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IR-B siRNA that worked in the DU145 cells we were able to also 
effectively silence IR-B in a breast cancer cell line (Figure S1C 
in Supplementary Material). We found that silencing the IR-B 
isoform in the DU145 cells resulted in a significant decrease in 
basal cell proliferation as measured by cell counting (p < 0.01; 
Figure 2D). Addition of 25 ng/ml of IGF-II or insulin alone to the 
DU145 cells significantly increased cell proliferation (p <  0.01 
and p < 0.05, respectively), with IGF-II having the greatest effect. 
FigUre 2 | (a) RT-PCR blot in which siRNA (10, 25, and 50  nM) was used to specifically silence IR-B in DU145 cells. Cells treated with a non-silencing 
(NS) siRNA acting as a negative control. After 24  h, sample RNA was extracted and RT-PCR was used to assess the expression of the IR-B isoform. 
This is representative of blots performed at least three times. (B) Representative RT-PCR blot shows the effect of 50  nM IR-B siRNA in DU145 cells after 
24, 48, and 72  h of treatment. A  non-silencing siRNA acted as a negative control. This is representative of blots performed at least three times. 
(c)  Q-PCR ΔΔCT IR-B/IR fold expression (%) normalized to non-silencing samples. IR-B was silenced for 24, 48, and 72  h in DU145 cells. Error bars 
represent the SE of the mean from three experiments each repeated in duplicate (n =  3). (D) DU145 cells were seeded in six well plates (0.1 ×  106 cells 
per well) in the presence or absence of target siRNA to the IR-B or non-silencing (NS) siRNA for 24  h and then switched to serum-free media for a 
further 24  h followed by dosing with IGF-II or insulin for 48  h. Changes in cell proliferation were assessed by direct count of viable cells in a 
hemocytometer. Results shown are the mean of three independent experiments each repeated in triplicate. Data are represented as mean ±  SEM.
(Continued)
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FigUre 2 | continued 
(e) (i) DU145 cells were seeded in 6 well plates (0.1 × 106 cells per well) in the presence or absence of target siRNA to the IR-B or non-silencing (NS) siRNA for 
24 h and then switched to serum-free media for a further 24 h followed by dosing with IGF-II or insulin for 30 min. Western blotting was performed to show 
protein abundance of p-AKT/AKT, p-MAPK/MAPK, and p-IGF-IR/IGF-IR (n = 3 experiments). (ii) shows a western blot and optical density measurements for 
levels of IR-β following IR-B silencing and (iii–v) shows the mean (n = 3) optical densitometry measurements from the western blots for p-AKT/AKT, p-MAPK/
MAPK, and p-IGF-IR/IGF-IR respectively: a representative example of which is shown in (e) (i).
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Silencing the IR-B isoform did not affect the response to IGF-II, 
whereas the response to insulin was blocked (Figure  2D). We 
also assessed the acute signaling response to IGF-II and insulin 
in the presence or absence of siRNA to IR-B. We showed effective 
silencing of IR-B using RT-PCR (Figures 2A–C) and Figure 2Eii 
indicates that protein levels of IR-β were also reduced. With Akt 
activation, we found that IR-B knockdown alone had no effect. 
We observed that after 30 min of treatment IGF-II and insulin 
each induced a significant increase in Akt activation that was 
unaffected when IR-B was silenced. There were no significant 
effects of either IGF-II or insulin in the presence or absence of 
siRNA to IR-B on p-MAPK or p-IGF-IR. We did, however, notice 
that with IR-B silenced alone there was a suggestion that MAPK 
was activated.
Exposure to Varying Concentrations of Glucose
We performed a dose response and exposed the DU145 
cells to increasing levels of glucose (5, 9, and 25  mM). Using 
RT-PCR, we found that the ratio of IR-B to IR-A increased in 
9  mM that was not increased further with 25  mM concentra-
tions of glucose (Figure  3Ai,ii). We further demonstrated 
that the effect of glucose on increasing the IRB:IR-A ratio was 
specific and not due to changes in osmolarity as exposing the 
cells to 5  mM d-glucose supplemented to 9 and 25  mM with 
l-glucose (that the cells are unable to metabolize) had no effect 
(Figure 3Ai,ii). We then performed a time course and exposed 
the DU145 cells to normal (5 mM) or high (25 mM; concentra-
tions routinely used in cell culture) levels of glucose in SFM for 
up to 72 h. Using RT-PCR, we found that the ratio of IR-B to 
IR-A increased when the cells were exposed to high glucose 
conditions (as we observed in Figure 3A): this occurred from 
the earliest time point of 6 h and was maintained for up to 72 h 
(data not shown). RT-PCR data confirmed that after 48 h, the 
IR-B mRNA expression was upregulated significantly in 25 mM 
glucose conditions in both GM and SFM (Figure  3B). q-PCR 
was used to measure the quantitative fold change of the IR-B 
isoform compared to the IR at 48 h: the IR-B isoform increased 
1.9-fold (in GM) and 2.8-fold (in SFM) compared to total IR 
mRNA under hyperglycemic conditions. We also showed that 
the effect of the high glucose in increasing the IR-B isoform was 
reversible when the cells were returned to normal glucose media 
(Figure S1D in Supplementary Material). In addition, absolute 
IR-B and total IR message levels, compared to the reference gene, 
did not change significantly in GM, whereas in SFM, levels of 
absolute IR-B were decreased (p < 0.05) and absolute levels of IR 
were increased (p < 0.05) in normal compared to hyperglycemic 
conditions (Figure  3C). Using western immunoblotting, we 
observed that total levels of the IR protein were significantly 
reduced (p < 0.05) in SFM containing 5 mM compared to 25 mM 
glucose after 48 h that was sustained for 72 h (Figure 3Di,ii), 
which did not mirror the changes observed at the mRNA level. 
We did not observe this hyperglycemia-induced increase in the 
IR-B isoform with LNCaP, PC3, or VCaP cells, that all inherently 
express predominantly IR-A (Figures S1E–G in Supplementary 
Material); but a similar effect was observed both in normal breast 
epithelial cells (MCF-10A) and in the HS578T breast cancer cell 
line (Figure 3E).
Exposure to Varying Concentrations of Glucose in 
the Presence of IGF-II and Insulin
Figure  4A confirms the data in Figure  3 showing that with 
DU145 cells high glucose compared to normal glucose condi-
tions increases the ratio of the IR-B to IR-A isoform. In addition, 
using q-PCR, we confirmed that the IR-B isoform was increased 
relative to the absolute levels of the IR mRNA under hypergly-
cemic conditions and that, in both concentrations of glucose, 
IGF-II and insulin each down-regulated the IR-B isoform 
compared to their respective controls (p <  0.05, respectively; 
Figure 4B). This shows that in normal glucose conditions in the 
presence or absence of insulin/IGF-II, the predominant isoform 
appears to be IR-A. Under hyperglycemic conditions, IR-B is 
the predominant isoform, but clearly on exposure to IGF-II/
insulin the isoform ratio can be reverted back to mainly IR-A. 
Figure 4C shows that basal cell proliferation was unaffected by 
altering glucose concentrations. However, increasing levels of 
glucose negated the ability of insulin to increase proliferation 
and reduced the proliferative response to IGF-II (Figure  4C) 
consistent with the observed proliferative effects of insulin 
and IGF-II in high glucose that were observed in Figure  2D. 
In high glucose, when the proportion of IR-B was increased, 
the changes in response to insulin and IGF-II were the opposite 
to those observed when the proportion of IR-B was reduced 
by siRNA. Figures 4D,E indicate that migration in treated and 
untreated samples was evident at 12 h and basal migration was 
unaffected by altering levels of glucose. By 36 h IGF-II induced 
more migration in normal compared to high glucose (p < 0.05): 
consistent with a greater response to IGF-II when there was more 
IR-A compared to IR-B, whereas the opposite was observed for 
insulin: cells responded better to insulin in high compared to 
normal levels of glucose (p <  0.05): consistent with a greater 
response to insulin when there was an increase in IR-B compared 
with IR-A.
insulin receptor isoform Profile in 
Prostate Tissue samples
We assessed the overall difference in expression of the isoforms 
in the 37 pairs of samples (benign and cancer) and found that 
the IR-A isoform tended overall to be greater by 9.1% (p = 0.09) 
in the cancerous regions of the samples compared to the benign 
regions. There was considerable heterogeneity between samples 
with the majority of samples exhibiting predominantly the IR-A 
isoform in both benign and cancerous regions. There were, how-
ever, exceptions where the IR-B isoform predominated. The IR-A 
isoform was greater in the cancer, compared to benign regions in 
26 pairs (by 20.8%; p < 0.001). Only six pairs showed a reduced 
proportion of the IR-A isoform in the cancer regions (by 33.4%: 
p < 0.05) with no difference in expression observed in five pairs 
(Figures 5A,B).
DiscUssiOn
Men who develop PCa increasingly have one of the co-mor-
bidities associated with a Western lifestyle (obesity, metabolic 
syndrome or diabetes). These co-morbidities are characterized 
FigUre 3 | DU145 cells were seeded in T25 flasks (0.6 × 106 cells) in 5 mM d-glucose containing gM.
(Continued)
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FigUre 3 | continued 
After 24 h, the media was changed to 5, 9, and 25 mM d-glucose or 5 mM d-glucose supplemented to 9 and 25 mM with l-glucose-containing GM for a further 
48 h. RNA was extracted and reversed to cDNA. (a) (i,ii) RT-PCR analysis to assess the expression of the IR isoforms and the associated arbitrary units indicating 
the changes in the ratio of the IR isoforms respectively. DU145 cells were seeded in T25 flasks (0.6 × 106 cells) in 5 mM GM. After 24 h, the media was changed to 
25 or 5 mM glucose-containing GM or SFM, respectively, for a further 48 h. RNA was extracted and reversed to cDNA. (B) RT-PCR analysis to assess the 
expression of the IR isoforms. (c) q-PCR data comparing fold change of the relative IR-B gene expression compared to the IR or housekeeping gene 18s (RF). Error 
bars represent the SE of the mean from three experiments each repeated in duplicate (n = 3). (D) (i) A representative western blot to show IR protein abundance in 
DU145 cells after being placed in 25 or 5 mM glucose conditions for different time points. Protein was extracted after 48 and 72 h and detected by western blotting 
using an IR (95 kDa) antibody. Housekeeping protein β-actin (43 kDa) was used as loading control. (D) (ii) graph showing fold changes in densitometry for IR protein 
relative to loading control. Error bars represent the SE of the mean of three repeats (n = 3). (e) A representative RT-PCR blot of IR isoform expression in MCF10A 
and Hs578T cells after 48 h exposure in 25 and 5 mM glucose SFM after being seeded for 24 h in 5 mM glucose GM. Relative OD ratio of IR-B isoforms in the 
MCF10A cell line (n = 3). Relative OD ratio of IR-B isoforms in Hs578T cells (n = 1).
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by hyperinsulinemia, hyperglycemia, and increased expression of 
IGF-I and -II that have each been associated with poor prognosis 
and more aggressive cancers that exhibit increased metabolism 
and increased glucose uptake (13–15). The IR has two isoforms 
IR-A and IR-B: IR-A has a higher affinity for IGF-II comparable 
to that for insulin, whereas the IR-B isoform predominantly 
binds to insulin.
It has been reported previously that the IR-A isoform is 
upregulated in a number of different tumor types, including those 
of the breast, colon, and lung (6). Despite assessing changes in a 
FigUre 4 | (a) DU 145 cells were seeded at 0.3 × 106 cells per T25 flask in 5 mM glucose GM for 24 h before being changed to 25 or 5 mM glucose-containing 
SFM conditions for a further 24 h. Cells were then treated with 100 ng/ml IGF-II or insulin for 48 h: mRNA was analysis by RT-PCR. (B) The fold change in IR-B/IR 
(Continued)
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was assessed by q-PCR. Error bars represent the standard error of the mean from three experiments each repeated in duplicate (n = 3). (c) DU145 were seeded in 
24 well plates (0.01106 per well) in 5 mM glucose-containing GM for 24 h and then changed to either 5 or 25 mM glucose-containing SFM for 48 h, followed by 
dosing with either 100 ng/ml of IGF-II or insulin for another 72 h. Proliferative activity was detected by TTI assay. Error bars represents the SE of the mean from five 
experiments each repeated in triplicate (n = 5). (D) DU145 cells were seeded into culture-inserts in 6 well plates in 5 mM GM. After 24 h, cells were treated with either 
100 ng/ml IGF-II or insulin in either 25 mM or 5 mM-glucose containing SFM. Pictures were taken at time 0, 12, and 36 h. These are representative of experiments 
repeated three times. (e) Densitometry shows the fold change of the gap relative to time 0. Error bars represent the SE of the mean of three repeats (n = 3).
FigUre 4 | continued
FigUre 5 | continued
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FigUre 5 | (a) FFPE patient samples were collected from patients diagnosed with adenocarcinoma of the prostate. RT-PCR was used to assess the levels of the 
IR-A and -B isoforms. (B) Graph showing the percentage change in the IR-A isoform relative to IR-B. Error bars represent the SE of the mean, where p < 0.05 
represents statistical significance. B, benign; C, cancer.
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relatively small cohort of 37 PCa patients, we observed similar 
changes: of the 37 paired samples the IR-A isoform was greater 
overall in the cancerous regions of the samples compared to the 
benign regions adjacent to the tumor tissue and was the predomi-
nant isoform in the cancer compared to benign regions in 26 pairs. 
This is consistent with a previous study that examined tissue from 
30 samples (11). We noticed considerable heterogeneity between 
samples with the IR-A being predominant in the benign tissue of 
some pairs and exceptions where the IR-B isoform predominated. 
Heni et al. compared the IR isoform ratio, in histologically benign 
prostatic tissue adjacent to the primary malignant cancer. The 
authors reported that the IR-A isoform was predominant in PCa 
tissue and was reduced in benign tissue adjacent to the tumor 
tissue, but that this difference in isoform expression between 
tumor and benign tissue was only significant when comparing 
tumor tissue to tissue derived from an entirely benign prostate 
(11). Prostatic intraepithelial neoplasia (PIN) describes dysplas-
tic changes in prostate cells that line the prostate gland and is 
considered to be a pre-malignancy, or carcinoma in  situ of the 
prostate gland. PIN coexists with cancer in the majority of cases, 
but retains an intact or fragmented basal cell layer, unlike cancer, 
which lacks a basal cell layer (16). As the benign regions we 
studied were adjacent to tumor tissue in the same sample, it is 
possible that for some cases areas of PIN were included which 
may explain why some of our patient samples had more IR-A than 
IR-B in the benign region. Another, more interesting, possibility 
relates to reports of the common occurrence of loss of imprinting 
of the IGF-II gene in PCas (17) that has been described as a field 
effect throughout the prostate (18). We have shown that exposure 
of PCa cells to IGF-II results in a suppression of the IR-B isoform 
and, therefore, increased expression of IGF-II, due to loss of 
imprinting throughout the prostate could result in suppressed 
IR-B and the predominance of IR-A throughout the prostate. An 
examination of benign prostate samples from cases of benign 
prostatic hypertrophy (BPH) that are cancer free compared with 
cancers, with and without the loss of imprinting of IGF-II, would 
be required to establish this point. Importantly, since IR-A and 
R-B can only be distinguished by RT-PCR from total tissue RNA 
extract the proportions could be influenced by non-tumor cells or 
infiltrating leukocytes that might express lower levels than tumor 
cells and in future studies it would be interesting to know what 
proportion of the cells were tumor cells and that this was similar 
in each sample.
In addition to assessing levels of the IR isoforms in vivo, we 
also looked in vitro and observed that three (LNCaP, PC-3, and 
VCaP) of our four cell lines displayed a similar profile to the 
cancer tissue and expressed more IR-A than IR-B. Only one 
PCa cell line we examined expressed more IR-B than A (DU145 
cells). We then exposed PCa cells to different levels of glucose 
to mimic normal and hyperglycemic conditions: we observed 
that when DU145 cells were exposed to normal, physiologic 
levels of glucose (5 mM) they predominantly expressed the IR-A 
isoform but when exposed to hyperglycemic levels of glucose 
(25  mM) the IR-B isoform was the main isoform expressed. 
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In the other PCa cell lines that we examined (LNCaP, VCaP, 
or PC3), all of which inherently contained less than 10% of 
their IR in the IR-B isoform, exposure to high glucose did not 
increase the low proportion of IR-B. We did, however, observe 
that the isoforms responded similarly to high glucose with 
an increase in IR-B in breast epithelial cells (MCF-10A and 
HS578T cells). So it appeared that for the majority of PCa cell 
lines the IR-A isoform predominated in either concentration 
of glucose, but in DU145 cells (and other non-prostate cell 
lines), the isoform ratio could be manipulated by increasing 
the concentrations of the glucose and switching from an IR-A 
to an IR-B dominant phenotype. An IR-B-dominant phenotype 
would presumably be more responsive to insulin and has been 
associated with a more differentiated phenotype in a number 
of different tissues, including adipocytes, hepatocytes, and in 
thyroid cancer (19–21). Furthermore, we did observe that a 
proportion of our paired patient samples also exhibited more 
IR-B than A in the cancer compared to the benign region. The 
IR-A isoform appears to be dominant in most cancer cell lines 
and in vivo which is also consistent with a reduction in the IR-B 
being associated with poorly differentiated cells, as observed in 
many cancers.
As insulin and IGF-II are the ligands for IR and their levels 
and/or availability may be increased in men with PCa who are 
obese or have type 2 diabetes: we also assessed alterations in IR 
isoforms following exposure to these agents in both concentra-
tions of glucose in DU145 cells. Regardless of glucose concentra-
tions, the addition of either IGF-II or insulin both reduced IR-B 
culminating in a relative increase in IR-A (that has a high affinity 
for IGF-II). In the PCa cell lines that expressed very low levels of 
IR-B, we observed that these levels did not respond to siRNA or 
change with altered glucose levels; this may be due to problems 
with the splicing mechanisms or could be due to instability of 
IR-B mRNA resulting in no observed changes in these cells. In the 
DU145 cell line, in which the IR-B isoform did increase in condi-
tions of high glucose, upon exposure to IGF-II or insulin again 
the predominant isoform was IR-A. Expression of this isoform 
could potentially enable cancer cells to respond more effectively 
to IGF-II, which is known to be over-expressed by most cancers, 
including that of the prostate irrespective of glucose conditions. 
This may be a contributing factor to why obese patients that 
develop PCa have more aggressive disease and a higher mortality 
rate (22–24).
We also assessed the consequences of changes in IR isoform by 
examining alterations in phenotype in the DU145 cells in which 
the isoform ratio was altered following exposure to increased 
levels of glucose or suppressed by siRNA. We observed that 
insulin induced significantly more migration when the cells were 
exposed to high concentrations of glucose (higher IR-B) than it 
did in normal glucose conditions (higher IR-A) and conversely 
IGF-II promoted greater migration under the normal glucose 
conditions. While insulin was clearly more effective than IGF-II 
in hyperglycemic conditions (with higher IR-B), both were 
equally effective under normal glucose conditions. With prolif-
eration, IGF-II again promoted a greater proliferative response 
in normal (high IR-A) compared to high glucose conditions 
(high IR-B). In conditions of high glucose, we observed a smaller 
response to insulin compared with IGF-II even though the IR-B 
isoform was predominant. However, it did induce a significant 
increase in proliferation under normal glucose conditions. IGF-II 
and insulin were both less effective in high compared to low 
glucose conditions; thus, hyperglycemia induced both relative 
insulin- and IGF-II-resistance in terms of proliferation. Clearly, 
exposure to different concentrations of glucose will affect many 
other aspects of cell function in addition to altering the IR 
isoforms.
To investigate the responses to insulin and IGF-II further, 
we successfully developed siRNA to effectively silence the 
IR-B isoform; which in high glucose conditions left IR-A as 
the predominant isoform. We initially observed that silencing 
IR-B alone significantly inhibited cell growth, suggesting a 
role for the IR-B isoform in cell proliferation. This was not 
observed by Heidegger et al. when they silenced IR-B but they 
performed their experiments in GM as opposed to SFM, which 
may account for the observed differences (25). Upon silencing 
IR-B (increasing relative abundance of the IR-A isoform) the cells 
showed a similar significant proliferative response to IGF-II but 
were no longer able to respond to insulin stimulation, indicating 
the reliance of insulin on the IR-B isoform for inducing an 
increase in cell growth. As with the exposure to different glucose 
concentrations, we were unable to silence the IR-B isoform in 
the other PCa cell lines (LNCaP, VCaP, or PC3) that already 
expressed predominantly IR-A, but were able to knockdown 
the IR-B isoform similarly in MCF-7 breast cancer cells. The 
abundance of the IR-B in these cell lines (LNCaP, VCaP, or 
PC3) is already very low (less than 10% of the IR-B isoform 
relative to total levels if the IR) and so it would be technically 
difficult to assess effective knockdown of IR-B by agarose gel 
electrophoresis. Interestingly, the MCF-7 breast cancer cell 
line, in which IR-B silencing was also effective has comparable 
abundance of IR-A and -B, with IR-B being the predominant 
isoform in hyperglycemic conditions. We also assessed the 
acute signaling response to IGF-II and insulin in the presence 
or absence of siRNA to IR-B. With Akt activation, we found 
that IR-B knockdown alone had no effect. IGF-II and insulin 
each induced a significant increase in Akt activation that was 
unaffected when IR-B was silenced. With IGF-II this response 
correlated with the cell counting data, where the proliferative 
response to IGF-II was also unaffected when IR-B was knocked 
down. However, while the ability of insulin to induce prolifera-
tion was blocked when IR-B was silenced the activation of Akt 
was not affected, suggesting that Akt activation at this time point 
was not mediating the proliferative response to insulin via IR-B. 
There were no significant effects of either IGF-II or insulin in the 
presence or absence of siRNA to IR-B on p-MAPK, suggesting 
an alternative pathway may be responsible for mediating the 
proliferative effects of insulin via IR-B in these cells following 
30  min of treatment. The exposure time may be important in 
determining which pathways are activated as it has been reported 
that the internalization dynamics of IR-A and B (26) and the 
kinetics of signaling of the IGF-IR and IR (27) are different. 
Although insulin acutely activated Akt in the absence of IR-B to 
translate into a proliferative signal, it may need a more sustained 
signal. We have demonstrated that alternative splicing of the IR 
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can be manipulated by different exposures and that the rela-
tive levels of these isoforms will influence how the cancer cells 
respond to both insulin and IGF-II. Alterations in the isoforms 
in response to changes in their hormonal milieu (as a result of 
the co-morbidities linked to a Western lifestyle) could have a 
profound impact on how malignant cells behave and play a role 
in promoting carcinogenesis. A greater understanding of the 
mechanisms underlying changes in alternative splicing of the 
IR may provide additional targets for future cancer therapies.
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